ClinicalTrials.gov
public full text
Public Domain
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer#1171601
- Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer#1124545
- Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer#1126355
- Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer#833341
- A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB#1173320
Record · ID 891336
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive